Last updated 2026-07-30
TL;DR
Most people on off-label, intermittent-dose sirolimus notice mouth ulcers or fatigue within 1-2 weeks, lab changes (lipids, glucose, blood counts) by 4-8 weeks, and subjective effects (skin, joints, energy) reported anecdotally over 3-12 months. No completed human trial has measured lifespan or healthspan endpoints; the NIA's mouse data (9-14% median lifespan extension) is the real anchor, not human results.
What actually happens week by week on sirolimus?
There's no FDA-approved timeline for this because there's no FDA-approved use for longevity. Everything below comes from the transplant pharmacology literature, small off-label case series, and patterns reported in the online rapamycin-user community, not from a completed aging trial. Treat it as a rough map, not a guarantee. Week 1-2: absorption and first side effects. Sirolimus has an elimination half-life of roughly 57 to 63 hours in stable transplant patients, which is why it's dosed once weekly or every 3-5 days in most off-label longevity protocols instead of daily like the transplant label specifies [1]. The first thing most people notice, if anything, is a mouth ulcer (aphthous stomatitis) showing up somewhere between day 3 and day 14. This is one of the most consistently reported adverse effects of sirolimus across transplant trials, with rates of 8-25% depending on dose and population [1]. Week 4-8: labs start moving. This is when clinicians who monitor patients on off-label rapamycin typically order a follow-up panel: lipid panel, fasting glucose or HbA1c, CBC, and sometimes a trough level. Dyslipidemia (elevated LDL and triglycerides) is a labeled effect of sirolimus, seen in a meaningful share of transplant patients on standard daily dosing [1]. At the lower, intermittent doses used off-label, the magnitude is usually smaller, but nobody has published a large controlled dataset confirming exactly how much smaller. Month 3-6: this is where anecdotal 'before and after' reports cluster, things like improved skin texture, better joint comfort, subjective energy changes. These are self-reported, unblinded, and not verified in controlled human trials. If you're comparing your own experience against what others describe, sirolimus before and after collects that anecdotal pattern, but it is not clinical evidence of anything. Year 1 and beyond: this is where the story runs out. There is no completed human trial that has followed people on off-label rapamycin for years and measured mortality, frailty, or disease incidence as an endpoint. Everything past month 6 is either mouse data extrapolated to humans, or individual experience with no control group.
Is there a human trial that has actually measured whether sirolimus extends lifespan?
No. As of 2026, there is no completed randomized controlled trial in humans measuring lifespan extension, mortality reduction, or validated aging biomarkers as a primary endpoint for off-label rapamycin use in healthy adults. This is the single most important fact in the whole topic, and it doesn't change no matter how good the mouse data looks. What does exist: the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), a crowdfunded study run through AgelessRx, looked at low-dose rapamycin (5mg or 10mg weekly) in adults over roughly 48-56 weeks, measuring frailty index, body composition, and patient-reported outcomes, not lifespan [2]. It found trends toward improved lean body mass and frailty scores in some dosing arms, but it was not powered as, and does not claim to be, a mortality or lifespan trial. Separately, small trials in older adults using everolimus (a rapamycin analog, an 'rapalog') showed improved influenza vaccine response when mTOR was inhibited before vaccination, published in Science Translational Medicine in 2014 [3]. That's a real, peer-reviewed human signal that mTOR inhibition changes immune function in older people. It is not a lifespan result. People sometimes conflate the two. So the honest state of the science: strong mechanistic rationale, strong mouse lifespan data, one immune-function human trial, one small frailty-focused human trial, and zero completed human lifespan trials. Anyone telling you sirolimus is 'proven' to extend human life is overstating the evidence. For a fuller breakdown of what the human evidence does and doesn't show, see sirolimus reviews and is sirolimus worth it.
What does the mouse lifespan data actually show, and how fast did results show up in mice?
The strongest evidence for rapamycin as a longevity compound comes from the National Institute on Aging's Interventions Testing Program (ITP), which tests candidate compounds across three genetically diverse mouse cohorts at three sites (Jackson Lab, University of Michigan, UT Health San Antonio). Rapamycin was the first compound in ITP history to extend both median and maximum lifespan in genetically heterogeneous mice, starting even when treatment began late in life, at 600 days of age (roughly equivalent to a 60-year-old human) [4]. In that 2009 Nature paper, rapamycin extended female median lifespan by about 14% and male median lifespan by about 9%, even though dosing started at an age point corresponding to late-middle-age in mice [4]. Follow-up ITP work has shown even larger effects at higher doses and with earlier starts, in some cohorts pushing lifespan extension past 25% in females at high doses started at 9 months of age [1]. The mouse timeline is fast relative to human life: treatment starts at roughly 9-20 months of age (mice live about 2.5-3.5 years total), and lifespan differences become statistically visible within the following 6-18 months of the study, because mouse lifespans compress the whole story into a window researchers can actually finish. That's the crux of the translation problem: a mouse study can report a complete lifespan result in about 2-3 years. A human lifespan study would need to follow people for decades, cost enormous sums, and control for everything else that happens to a person's health across that time. Nobody has funded or completed one.
How soon do side effects like mouth ulcers show up?
Mouth ulcers are usually the earliest and most noticeable side effect, often appearing within the first 1-3 weeks of starting or increasing a dose. In transplant-dose sirolimus trials, stomatitis and mucosal ulcers were reported in a meaningful minority of patients, and rates rise with higher trough levels [1]. At the lower once-weekly or twice-weekly doses used in off-label longevity protocols (commonly in the 3-10mg weekly range), ulcers are still reported by users and by physicians running off-label clinics, though systematic incidence data at these specific doses hasn't been published in a large controlled trial. Most people who get mouth ulcers on rapamycin describe them as similar to canker sores, appearing on the inside of the cheek or under the tongue, and resolving over 1-2 weeks even without stopping the drug. Some clinicians manage this with dose reduction, spacing doses further apart, or a brief pause. Other early effects people report in the first month include mild GI upset, headache, and occasionally acne-like skin eruptions. None of these are unique to rapamycin; they overlap with sensitivities to lots of drugs. What is specific to rapamycin's mechanism is that mTOR inhibition affects epithelial turnover, which is the likely reason mouth and gut mucosa are disproportionately affected early on.
When do lab changes (lipids, glucose, blood counts) show up, and how often should you retest?
| Mouth ulcers | Week 1-3 | As symptoms occur |
|---|---|---|
| Lipid panel changes | Week 4-8 | Every 3-6 months |
| Fasting glucose/HbA1c | Week 4-8 | Every 3-6 months |
| CBC (platelets, WBC) | Week 4-8 | Every 3-6 months |
| Trough level (if checked) | Week 1-2 after dose change | After any dose change |
Most off-label protocols recommend baseline labs before starting, then a follow-up panel at 4-8 weeks, then every 3-6 months if values are stable. This mirrors, loosely, the more frequent monitoring schedule used in transplant medicine, where sirolimus troughs and metabolic panels are checked much more often because doses are higher and the drug is combined with other immunosuppressants [1]. Lipids: dyslipidemia is a labeled adverse effect of sirolimus. In transplant trials, hypercholesterolemia and hypertriglyceridemia were reported in roughly a third or more of patients depending on dose and concomitant drugs [1]. At low, intermittent longevity-protocol doses, effects are typically smaller, but there's no large published dataset quantifying exactly how much smaller for weekly dosing in healthy adults specifically. Glucose: this is the counterintuitive one. mTOR inhibition improves insulin sensitivity in some mouse models but has been associated with impaired glucose tolerance and, in some transplant patients, new-onset diabetes after transplant (NODAT), particularly at higher, continuous doses combined with other immunosuppressants and corticosteroids [1]. Whether intermittent weekly dosing in otherwise healthy people carries meaningful metabolic risk is unresolved; it's exactly the kind of question that only a real trial answers. Blood counts: sirolimus can suppress bone marrow function, leading to lower platelet counts, anemia, or low white cell counts, more often at higher continuous doses [1]. A CBC at baseline and periodically after is standard practice among physicians who prescribe this off-label. | Lab or symptom | Typical first appearance | Usual monitoring interval |
Does sirolimus suppress the immune system at longevity doses, and how fast?
Yes, and this is the risk that gets underplayed the most. Sirolimus is FDA-approved as an immunosuppressant to prevent organ rejection in kidney transplant patients, and its mechanism, blocking mTOR signaling in T cells, directly dampens immune activation [1]. That's the whole reason it works as an anti-rejection drug, and it's also the plausible mechanism behind some of its anti-aging effects in mice (reduced chronic inflammation, or 'inflammaging'). Immune suppression can show up within days to weeks of starting, in the form of slower wound healing or a worse-than-usual response to a minor infection. At transplant doses this is well documented and expected. At the low, intermittent doses used off-label for longevity, the immune effect is presumably smaller, and the small human trial evidence actually points to something interesting: low-dose mTOR inhibition before flu vaccination improved antibody response in older adults in a randomized trial [3]. That's a case where less-is-different from more, more than less-of-the-same. But 'presumably smaller' is not the same as 'safe,' and there's no large safety trial establishing where that line is for otherwise-healthy people taking it for years. Practical implication: anyone on any rapamycin dosing schedule should tell their doctor before elective surgery, should be cautious around live vaccines, and should treat unexplained fevers or infections as something to get checked promptly, not waited out.
How does the off-label longevity protocol differ from the FDA-approved transplant protocol, and does that change the timeline?
Substantially, and this matters for how you read any of the timelines above. The FDA label for sirolimus (brand name Rapamune) is daily dosing to maintain a specific trough blood level, used together with other immunosuppressants, to prevent kidney transplant rejection [5]. Sirolimus and rapamycin are the same molecule; 'rapamycin' is the generic compound name discovered from Streptomyces hygroscopicus soil bacteria on Easter Island, and 'sirolimus' is the name used in its pharmaceutical formulation . Off-label longevity protocols almost universally use once-weekly or twice-weekly dosing at lower total doses (commonly 3-10mg once weekly, versus daily maintenance dosing in transplant patients), based on the pharmacokinetic argument that intermittent high peaks may hit mTORC1 (the target linked to aging benefits) while sparing mTORC2 (linked to more side effects) [1]. This is a reasonable pharmacological hypothesis. It is not proven in a large human trial. The PEARL trial's dosing arms (5mg and 10mg weekly) reflect this same intermittent-dosing logic [2]. Because of this dosing difference, much of the transplant-trial side-effect and timeline data (which used daily dosing) may overstate what happens at lower weekly doses, and understate what happens over years of accumulated exposure that hasn't been studied yet in healthy people. Anyone using it off-label is, functionally, participating in an uncontrolled natural experiment on a compressed personal timeline, not a supervised trial.
What's a realistic first month like on sirolimus, for someone starting it off-label?
Most people don't feel dramatically different in the first month. If anything happens, it's more likely to be a mild side effect than a noticeable benefit. Expect: possibly a mouth ulcer between week 1 and 3, maybe mild fatigue or GI upset in the first week or two as the body adjusts, and a follow-up lab draw around week 4-8 to check lipids, glucose, and blood counts. Most longevity-focused prescribers start conservatively, often 3-6mg once weekly, and adjust based on tolerance and labs rather than chasing a specific trough level the way transplant medicine does. If you want a fuller walk-through of what a first month typically involves, see sirolimus first month what to expect. What you should not expect in month one: measurable changes in disease risk, validated biological age reversal, or anything resembling the mouse lifespan data. Those mouse results took mice their entire remaining lifespan to show up, and mice don't live a month, they live two to three years. There is no human data showing month-one biomarker changes translate into anything resembling the 9-14% lifespan extension seen in mice [4].
What's the realistic long-term timeline (1+ years) and what don't we know yet?
Past 6-12 months, the honest answer is: we don't have a completed dataset. No published trial has followed off-label rapamycin users for multiple years measuring hard outcomes like mortality, cancer incidence, or cardiovascular events, the way the mouse ITP studies did. What exists past year one is a mix of case reports, physician experience shared informally, and the extrapolation from mouse biology. The PEARL trial's roughly year-long window is the longest controlled human data currently published on off-label-style dosing, and it measured frailty and body composition, not survival [2]. Longer studies are reportedly underway or being discussed in the longevity research community, but as of this writing none have published multi-year mortality results. This is the gap that matters most if you're deciding whether to start. The mouse data is genuinely strong and consistently replicated across independent NIA-funded sites [4] [1]. The human data on hard outcomes doesn't exist yet. Anyone framing this as a settled question, in either direction, is not representing the evidence accurately. If you're weighing the tradeoffs before deciding, sirolimus pros and cons and sirolimus success rate both lay out what 'success' can and can't mean given this gap.
If I decide to try it, how should I actually start (safely, with monitoring)?
If you go this route, it should be through a doctor who orders baseline labs, checks in at 4-8 weeks, and adjusts dose based on your actual numbers and side effects, not a fixed schedule copied from a forum post. Baseline bloodwork should include a lipid panel, fasting glucose or HbA1c, and a CBC at minimum; some clinicians add a sirolimus trough level a week or two after starting or after any dose change. Sirolimus Rx works with a provider-reviewed process that connects patients to a licensed prescriber and a pharmacy partner (Tailor Made Compounding is the pharmacy fulfilling these prescriptions) so dosing and monitoring happen under actual medical supervision rather than self-directed guesswork. That doesn't change the evidence gap described above, it just means if you're going to take on the off-label risk, you do it with labs, a prescriber who can adjust or stop the drug, and a documented plan, rather than blind.
Frequently asked questions
How long does it take to see results from sirolimus?
Side effects like mouth ulcers can appear within 1-3 weeks. Lab changes (lipids, glucose, blood counts) are typically checked at 4-8 weeks. Subjective effects on skin or energy are reported anecdotally over 3-12 months. No human trial has measured lifespan or disease-outcome results at any timepoint; that data doesn't exist yet.
Is there a human study proving sirolimus extends lifespan?
No. As of 2026 there is no completed human trial measuring lifespan or mortality with off-label sirolimus. The PEARL trial measured frailty and body composition over about a year, not survival. The strongest lifespan evidence remains in mice, from the NIA's Interventions Testing Program.
How much does rapamycin extend lifespan in mice?
In the NIA Interventions Testing Program's original 2009 study, rapamycin extended median lifespan by about 9% in males and 14% in females, even when started at 600 days of age (roughly a 60-year-old human equivalent). Later cohorts with higher doses and earlier starts showed larger effects, sometimes over 25% in females.
Are sirolimus and rapamycin the same drug?
Yes. Rapamycin is the generic compound name for the molecule discovered from Streptomyces hygroscopicus bacteria found on Easter Island. Sirolimus is the pharmaceutical name for the same compound, used in the FDA-approved drug Rapamune and related products.
When do mouth ulcers from sirolimus usually appear?
Most commonly within the first 1 to 3 weeks of starting or increasing a dose. They typically resemble canker sores, appear on inner cheeks or under the tongue, and often resolve within 1-2 weeks. Dose reduction or spacing doses further apart is a common management approach.
Does low-dose sirolimus suppress the immune system?
Sirolimus is FDA-approved as an immunosuppressant, and its mechanism (blocking mTOR in T cells) does dampen immune activation at any dose. At low intermittent doses the effect is presumably smaller, and one small human trial found low-dose mTOR inhibition actually improved flu vaccine response in older adults, but the long-term infection risk at longevity doses hasn't been studied in a large trial.
What labs should I get before and during sirolimus treatment?
Baseline lipid panel, fasting glucose or HbA1c, and a complete blood count are standard, with a possible sirolimus trough level after starting or changing dose. Most off-label protocols recheck labs at 4-8 weeks, then every 3-6 months if stable.
Is off-label rapamycin dosing different from the FDA-approved transplant dose?
Yes, substantially. The FDA label is for daily dosing to maintain a steady blood trough in transplant patients on combination immunosuppression. Off-label longevity protocols typically use once or twice weekly dosing at lower total amounts, based on the theory that intermittent peaks favor mTORC1 inhibition over mTORC2.
Can sirolimus cause high cholesterol or blood sugar problems?
Yes. Dyslipidemia (elevated LDL and triglycerides) is a labeled effect of sirolimus at transplant doses, and new-onset diabetes after transplant has been reported, more often with higher continuous dosing combined with other immunosuppressants. Effects at low weekly longevity doses are presumed smaller but not well quantified in published trials.
What is the PEARL trial and what did it actually find?
PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is a trial testing low-dose rapamycin (5mg and 10mg weekly) in adults over about a year, measuring frailty index and body composition, not lifespan or mortality. It's the longest published controlled human data on this style of dosing, but it isn't a longevity outcome trial.
Why hasn't anyone done a human lifespan trial for rapamycin yet?
Human lifespan trials require decades of follow-up, huge sample sizes, and enormous funding to control for the many other things that affect how long people live. Mouse studies compress the same question into 2-3 years because mice have short lifespans. No funder has completed a human trial with mortality as the endpoint.
What's the earliest sign that sirolimus is 'working' for someone taking it off-label?
There's no validated early biomarker proven to predict long-term benefit. People commonly report skin or joint changes around month 3-6, but these are self-reported and unverified. Lab shifts (lipids, glucose) by week 4-8 show the drug is biologically active, not that it's extending healthspan or lifespan.
Sources
- FDA, Rapamune (sirolimus) prescribing information: Sirolimus has an elimination half-life of approximately 57-63 hours and dosing/immunosuppression mechanism details
- Mannick et al., Science Translational Medicine, 2014: mTOR inhibition (everolimus) before influenza vaccination improved antibody response in older adults in a randomized trial
- Harrison et al., Nature, 2009: Rapamycin extended median lifespan in genetically heterogeneous mice even when started at 600 days of age, by about 9% in males and 14% in females
- NIA Interventions Testing Program, published results summary: Higher rapamycin doses and earlier treatment starts produced larger lifespan extension in later ITP cohorts
- NIH National Library of Medicine, PubChem sirolimus compound summary: Rapamycin was discovered from Streptomyces hygroscopicus and sirolimus is the same compound in pharmaceutical form